Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933 is a phase 1 interventional trial sponsored by Inhibrx Biosciences, Inc. As of 21 Nov 2026, it is recruiting participants. It studies Bevacizumab, Fluorouracil, INBRX-109, Irinotecan and 5 more drugs in Colorectal Adenocarcinoma and Ewing Sarcoma. The registry lists an enrollment of 411 participants at 37 sites in 6 countries. The registry lists a start date of 8 Oct 2018 and a primary completion date of 31 Dec 2028. 5 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03715933 |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Inhibrx Biosciences, Inc |
| Enrollment | 411 |
| Registered sites | 37 |
| Countries | 6 |
| Conditions | Colorectal Adenocarcinoma and Ewing Sarcoma |
| Drugs | Bevacizumab, Fluorouracil, INBRX-109, Irinotecan, Leucovorin, Temozolomide, Tipiracil / trifluridine, Carboplatin and Pemetrexed |
| Start | 8 Oct 2018 |
| Primary completion | 31 Dec 2028 |
| Study completion | 30 Jun 2029 |
| Last update posted | 8 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Clinical Lead
Inhibrx Biosciences, Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
37 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Honorhealth Research Institute
Scottsdale
Completed
- Precision Nextgen Oncology and Research
Beverly Hills
Kamalesh Sankhala, MDRecruiting - City of Hope
Duarte
Marwan Fakih, MDRecruiting - Valkyrie Clinical Trials
Los Angeles
David Berz, MDRecruiting - Children's Hospital of Orange County-Rady Children's Health
Orange
Dr. Elyssa Rubin, MDRecruiting - University of California, San Diego (ucsd) - Moores Cancer Center
San Diego
Withdrawn - University of California, San Francisco (ucsf)
San Francisco
Varun Monga, MDRecruiting - Sarcoma Oncology Center
Santa Monica
Sant P Chawla, MDRecruiting
- University of Colorado Hospital
Aurora
Christopher Lieu, MDRecruiting
- Emory University - Winship Cancer Institute
Atlanta
Olatunji Alese, MDRecruiting
- the University of Chicago
Chicago
Completed
- University of Michigan
Ann Arbor
Rashmi Chugh, MDRecruiting - Start Midwest Michigan, Pc
Grand Rapids
Nehal Lakhani, MDRecruiting
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York
Emily Slotkin, MDRecruiting
- Cincinnati Children's Hospital Medical Center
Cincinnati
Michael D Deel, MDRecruiting - Cleveland Clinic
Cleveland
Completed
- Oregon Health & Science University
Portland
Michael Heinrich, MDRecruiting
- Children's Hospital of Philadelphia- Center for Childhood Cancer Research
Philadelphia
Theodore Laetsch, MDRecruiting - University of Pennsylvania Abramson Cancer Center
Philadelphia
Lee Hartner, MDRecruiting
- Vanderbilt University School of Medicine
Nashville
Elizabeth Davis, MDRecruiting
- Ut Md Anderson Cancer Center
Houston
David Hong, MDRecruiting - Next Oncology
San Antonio
Completed
- University of Virginia
Charlottesville
Ludimila Cavalcante, MDRecruiting - Next Oncology - Virginia
Fairfax
Alexander Spira, MDRecruiting
- Great North Children's Hospital
London
Quentin Campbell-Hewson, MDRecruiting - the Royal Marsden Nhs Foundation Trust
London
Andrea Napolitano, MDRecruiting - University College London Hospital
London
Sandra Strauss, MDRecruiting - Royal Manchester Children's Hospital
Manchester
Bernadette Maria Dymphna BrennanRecruiting
- Hospital Universitario Vall D'Hebron
Barcelona
Elena Elez, MDRecruiting - Hospital de la Santa Creu I Sant Pau
Barcelona
Ana Sebio Garcia, MDRecruiting - Hospital Clinico San Carlos
Madrid
Antonio Casado HerraezRecruiting
- Centre Leon Berard
Lyon
Mehdi Brahmi, MDRecruiting - Gustave Roussy
Villejuif
Pablo Berlanga, MDRecruiting
- la Fondazione E L'Istituto Di Candiolo
Candiolo
Sandra Aliberti, MDRecruiting - Fondazione Irccs Istituto Nazionale Dei Tumori
Milan
Roberto Luksch, MDSalvatore Provenzano, MDRecruiting
- University Medical Center Groningen
Groningen
Jacco de Haan, MDRecruiting - Academisch Ziekenhuis Leiden
Leiden
André (Hans) Gelderblom, MDRecruiting
United States, by state
Outside the United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03715933
Each answer restates registry values shown on this page.
What is NCT03715933?
NCT03715933 is a phase 1 interventional trial sponsored by Inhibrx Biosciences, Inc. It studies Bevacizumab, Fluorouracil, INBRX-109, Irinotecan and 5 more drugs in Colorectal Adenocarcinoma and Ewing Sarcoma.
Is NCT03715933 recruiting?
As of 21 Nov 2026, it is recruiting participants. 32 of its 37 sites list their own status as recruiting.
Who leads NCT03715933?
The registry names Clinical Lead (study director, Inhibrx Biosciences, Inc) as the overall official.
Where does NCT03715933 run?
The registry lists 37 sites in 6 countries. Most sites are in these countries: United States (24), United Kingdom (4) and Spain (3).
Which drugs does NCT03715933 study?
The registered drug and biological interventions are Bevacizumab, Fluorouracil, INBRX-109, Irinotecan, Leucovorin, Temozolomide, Tipiracil / trifluridine, Carboplatin and Pemetrexed.
When is NCT03715933 expected to complete?
The registry lists a primary completion date of 31 Dec 2028 and a study completion date of 30 Jun 2029. The sponsor last updated the record on 8 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.